{
    "2020-07-17": [
        [
            {
                "time": "2020-07-23",
                "original_text": "Lilly Confirms Date and Conference Call for Second-Quarter 2020 Financial Results Announcement",
                "features": {
                    "keywords": [
                        "Lilly",
                        "conference call",
                        "financial results"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-07-24",
                "original_text": "South Korea approves human trials of Celltrion's COVID-19 antibody drug",
                "features": {
                    "keywords": [
                        "South Korea",
                        "Celltrion",
                        "COVID-19",
                        "antibody drug",
                        "human trials"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotechnology",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2020-07-25",
                "original_text": "Lilly's Mirikizumab Superior to CosentyxÂ® (secukinumab) in a Phase 3 Study for Patients with Moderate to Severe Plaque Psoriasis",
                "features": {
                    "keywords": [
                        "Lilly",
                        "Mirikizumab",
                        "Cosentyx",
                        "Phase 3",
                        "psoriasis"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}